Private Equity
Cincinnati-based Cintrifuse has raised a little more than $34 million of a targeted $85 million fund, according to a regulatory filing. The syndicate venture fund invests in early-stage funds and entrepreneurs nationwide. Its previous fund was $57 million.
1 min read · 27 June 2018
5 min read · 27 June 2018
Harbinger Ventures has raised over $10 million for its second fund, according to an SEC filing. The target is $30 million. The Boulder-based venture firm invests in female entrepreneurs and CEOs.
1 min read · 27 June 2018
Durham, North Carolina-based Precision BioScience, a genome editing system provider, has raised $110 million in Series B financing. ArrowMark Partners led the round with participation from other investors that included Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, Leerink Partners, venBio, F-Prime and Osage University Partners.
1 min read · 27 June 2018
IQ Capital, a UK-based venture firm, has raised 92 million pounds for its third fund. The target is 125 million pounds. The fund will invest in UK-based deeptech companies.
4 min read · 27 June 2018
Philadelphia-based Carisma Therapeutics Inc, a developer of macrophage-based immunotherapeutics, has raised $53 million in Series A financing. AbbVie Ventures and HealthCap led the round with participation from other investors that included IP Group, Penn Medicine, Grazia Equity, Wellington Partners, TPG Biotech, MRL Ventures Fund and Agent Capital.
1 min read · 27 June 2018
3 min read · 27 June 2018
The federal government's Venture Capital Catalyst Initiative (VCCI) has completed its first round of investments, backing five funds-of-funds managers. They include managers backed by VCCI’s predecessor, the Venture Capital Action Plan. They are: HarbourVest Partners, Kensington Capital Partners, Northleaf Capital Partners and Teralys Capital. U.S.-based manager Hamilton Lane also secured a commitment. Funds-of-funds commitments, totalling $350 million of VCCI's $400 million pool, mark the program's Stream 1, which focuses on capitalizing Canadian venture capital funds, including those investing in late-stage opportunities. Stream 2 will commit $50 million to key market gaps.
5 min read · 26 June 2018
Waltham, Massachusetts-based Skyhawk Therapeutics Inc, a developer of small molecule therapeutics that correct RNA expression, has secured $40 million in funding. The company's investors include Alexandria Venture Investments, GreatPoint Ventures, ShangPharma Innovation and Agent Capital.
1 min read · 26 June 2018
2 min read · 26 June 2018
